Welcome to our dedicated page for NewAmsterdam Pha news (Ticker: namsw), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pha stock.
NewAmsterdam Pharma (NAMSW) is a clinical-stage biopharmaceutical company advancing obicetrapib, a novel oral CETP inhibitor targeting LDL cholesterol reduction in high-risk cardiovascular patients. This news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.
Access timely announcements about ongoing Phase 3 trials (BROOKLYN, BROADWAY, PREVAIL), partnership agreements, and intellectual property advancements. Our curated news collection serves as a centralized resource for tracking obicetrapib's progress through late-stage development and potential commercialization.
Key updates include trial result disclosures, FDA/EMA regulatory communications, manufacturing partnerships, and peer-reviewed publication highlights. All content is verified through primary sources to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for direct access to NewAmsterdam's latest press releases and objective updates about their cardiovascular pipeline. Monitor critical developments in lipid management therapeutics through our maintained news archive.
NewAmsterdam Pharma (NAMS) has granted inducement share options to eleven new non-executive employees. The grant, approved by the Company's Compensation Committee, covers 197,000 ordinary shares under the 2024 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $20.03, matching the closing price of NAMS shares on May 1, 2025. The options will vest over a four-year period, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments, contingent on continued employment.
NewAmsterdam Pharma will present new clinical and preclinical data for its drug obicetrapib at the 93rd European Atherosclerosis Society Congress in Glasgow. The presentations include results from the BROADWAY and TANDEM Phase 3 trials, focusing on the drug's effectiveness in treating hypercholesterolemia.
Key presentations will highlight the fixed-dose combination of obicetrapib with ezetimibe for LDL-C reduction and the drug's safety profile in high cardiovascular risk patients. Additional sessions will cover obicetrapib's impact on atherosclerosis, vascular inflammation, and its effects when combined with moderate-dose statins.
The congress, scheduled for May 4-7, 2025, will feature multiple presentations across different sessions, including late-breaker oral presentations, poster networking sessions, and workshops. The research demonstrates obicetrapib's potential as a novel, oral, low-dose therapy for patients with elevated LDL-C who don't respond well to existing treatments.
NewAmsterdam Pharma (Nasdaq: NAMS) has appointed Adele Gulfo as an independent director to its Board of Directors. Gulfo brings over three decades of healthcare industry experience, notably in launching blockbuster medicines including LIPITOR® and CRESTOR®.
The appointment comes as NewAmsterdam prepares for the potential launch of obicetrapib next year. Gulfo most recently served as CEO for Sumitomo Pharma America's Biopharma Commercial Unit, overseeing commercial and development portfolios across multiple therapeutic areas. Her previous roles include executive positions at Sumitovant Biopharma, Roivant Sciences, Pfizer (where she led the $12 billion U.S. primary care business), and AstraZeneca.
NewAmsterdam is developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The company has recently reported positive readouts from three pivotal Phase 3 clinical trials.
NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee has approved inducement share options for five non-executive new hires, covering 133,000 ordinary shares. The options were granted under the company's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $18.38 per share, matching the closing market price on April 1, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment.
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's Chief Financial Officer, Ian Somaiya, will engage in a virtual fireside chat on Monday, April 7, 2025, at 12:45 p.m. ET. Investors and interested parties can access the live webcast through the investor relations section at ir.newamsterdampharma.com, with an archived replay available afterward on the company's website.
NewAmsterdam Pharma (NAMS) reported its full year 2024 financial results and corporate updates. The company highlighted positive results from three Phase 3 trials for obicetrapib, their oral non-statin medicine for cardiovascular disease patients with elevated LDL-C. The BROADWAY trial showed 33% LDL-C reduction, TANDEM trial achieved 49% reduction, and BROOKLYN trial demonstrated 36% reduction compared to placebo.
Financial highlights include $834.2 million in cash and marketable securities, revenue of $45.6 million (up from $14.1M in 2023), R&D expenses of $151.4 million, and net loss of $241.6 million. The company secured patent protection for obicetrapib until 2043 and expects EMA submission in 2H25 through partner Menarini.
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk, has announced its participation in multiple investor conferences in March 2025.
The company will attend the TD Cowen 45th Annual Healthcare Conference in Boston on March 4-5, where CEO Michael Davidson and CFO Ian Somaiya will present a corporate overview on March 4 at 1:50 p.m. ET.
Additionally, NAMS will participate in the Leerink Partners Global Healthcare Conference in Miami on March 10, with Dr. Davidson presenting at 8:00 a.m. ET, and the Jefferies Biotech on the Beach Summit in Miami on March 12, where management will be available for one-on-one meetings.
Live webcasts of the presentations will be accessible through the investor relations section of the company's website, with archived replays available afterward.
NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee has approved inducement share options for four non-executive new hires. The grants cover 138,000 ordinary shares under the company's 2024 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4).
The share options were granted at an exercise price of $21.36, matching the closing market price of NAMS ordinary shares on February 3, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting in 36 equal monthly installments, contingent on continued employment.
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced its participation in the Guggenheim SMID Cap Biotech Conference.
The company's Chief Financial Officer, Ian Somaiya, will engage in a fireside chat on Wednesday, February 5, 2025, at 10:00 a.m. ET. Investors and interested parties can access the live webcast through NewAmsterdam Pharma's investor relations website at ir.newamsterdampharma.com. An archived replay will be available on the company's website following the live presentation.
NewAmsterdam Pharma (NAMS) provided updates on its obicetrapib clinical development program and 2025 strategic priorities. The company reported positive topline results from three Phase 3 trials in 2024: BROADWAY showed 33% LDL-C reduction and 21% MACE reduction; TANDEM achieved 49% LDL-C reduction with fixed-dose combination; and BROOKLYN demonstrated 36% LDL-C reduction.
The company completed enrollment of over 9,500 patients in the PREVAIL cardiovascular outcomes trial. Additional data from these trials will be presented throughout 2025, supporting global regulatory filings including EMA submission in 2H25. The Phase 2 VINCENT trial, exploring obicetrapib's effect on Lp(a), is expected to report data in 2H25.
NewAmsterdam ended 2024 with an unaudited cash balance of $835 million following an oversubscribed public offering. The company secured patent protection for obicetrapib until July 2043 and is focusing on commercial readiness with manufacturing capacity establishment.
FAQ
What is the current stock price of NewAmsterdam Pha (namsw)?
